Amneal Pharmaceuticals (AMRX) Cash & Equivalents (2017 - 2026)

Amneal Pharmaceuticals' Cash & Equivalents history runs 10 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 36.59% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $4.2 million (down 36.59% YoY), while the FY2025 annual figure was $282.0 million, up 3469.99% from the prior year.
• Cash & Equivalents was $4.2 million for Q1 2026 at Amneal Pharmaceuticals, down from $282.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $282.0 million in Q4 2025 to a low of $4.2 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $54.2 million across 5 years, with a median of $8.6 million in 2022.
• Biggest YoY gain for Cash & Equivalents was 5562.55% in 2022; the steepest drop was 97.77% in 2022.
• A 5-year view of Cash & Equivalents shows it stood at $26.0 million in 2022, then sank by 70.88% to $7.6 million in 2023, then climbed by 4.43% to $7.9 million in 2024, then jumped by 3469.99% to $282.0 million in 2025, then sank by 98.52% to $4.2 million in 2026.
• The last three Cash & Equivalents figures came in at $4.2 million (Q1 2026), $282.0 million (Q4 2025), and $34.7 million (Q3 2025), per Business Quant data.